title: [Peri-operative management of disease modifying anti-rheumatic drugs: recommendations based on a meta-analysis].
abstract: The objective of this paper is make recommendations for the perioperative management of antirheumatic treatment based on the best available evidence. A systematic review was performed including studies in which patients with rheumatic diseases treated with biological and non-biological disease-modifying antirheumatic drugs (DMARDs) had undergone surgery. A total of 5,285 studies were recorded, of which 27 were finally included. These contained information on 5,268 patients and 7,933 surgeries. The majority were women (mean age 55 years) were diagnosed with rheumatoid arthritis, and the most studied drug was methotrexate (MTX). The final recommendations include: maintaining treatment with MTX or leflunomide in the perioperative period in the absence of other risk factors for postoperative complications (Level of Evidence 1c, Grade D recommendation). Biological DMARDs should be temporarily suspended, or the surgery scheduled as far as possible from the last dose, and, if there were other risk factors a space at least two doses (Level of Evidence 2c; Grade D recommendation).
authors.affiliation: Servicio de Reumatología, Hospital Universitario La Paz, Madrid, España. leticiadelolmo@hotmail.es
authors.forename: L
authors.initials: L
authors.lastname: Del Olmo
authors.forename: B
authors.initials: B
authors.lastname: Hernández
authors.forename: M
authors.initials: M
authors.lastname: Galindo-Izquierdo
authors.forename: D
authors.initials: D
authors.lastname: Tébar
authors.forename: A
authors.initials: A
authors.lastname: Balsa
authors.forename: L
authors.initials: L
authors.lastname: Carmona
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D019990:Perioperative Care / Q000379:methods*; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control*; D012216:Rheumatic Diseases / Q000188:drug therapy / Q000601:surgery*; D012307:Risk Factors; D016896:Treatment Outcome; D028761:Withholding Treatment
chemical_list: D018501:Antirheumatic Agents